Preliminary Flu Vaccine Effectiveness (VE) Data for 2022-2023
CDC Reference (severe flu outcomes): Olson, Lewis, Tenforde 2023 [4.5 MB, 25 pages]
Marshfield, WI Reference (medically attended flu illness): McLean, et al., 2023
New Vaccine Surveillance Network (NVSN)
Vaccine Effectiveness | |||||||
---|---|---|---|---|---|---|---|
Influenza positive | Influenza negative1 | Adjusted2 | |||||
N vaccinated /Total | (%) | N vaccinated /Total | (%) | VE % | 95% CI | ||
Influenza A All 6 mos – 17 years | 123/640 | 19 | 750/2256 | 33 | 49 | (36 to 60) | |
Inpatient | 19/131 | 15 | 288/913 | 32 | 68 | (46 to 81) | |
ED | 104/507 | 21 | 461/1330 | 35 | 42 | (25 to 56) | |
A/H3N2 | 98/478 | 21 | 750/2256 | 33 | 45 | (29 to 58) | |
A/H1N1pdm09 | 23/139 | 17 | 750/2256 | 33 | 56 | (28 to 72) |
1 Persons testing negative for both influenza and SARS-CoV-2 using molecular assays.
2 Multivariable logistic regression models adjusted for site, age, and calendar time.
Investigating Respiratory Viruses in the Acutely Ill (IVY) Network
Vaccine Effectiveness | ||||||
---|---|---|---|---|---|---|
Influenza positive | Influenza negative1 | Adjusted2 | ||||
N vaccinated /Total | (%) | N vaccinated /Total | (%) | VE % | 95% CI | |
≥18 years | 219/701 | 31 | 921/2130 | 43 | 43 | (30 to 54) |
18-64 years | 84/378 | 22 | 365/1021 | 36 | 51 | (33 to 64) |
≥65 years | 135/323 | 42 | 556/1109 | 50 | 35 | (13 to 52) |
Immunicompromised3 | 45/122 | 37 | 238/474 | 50 | 44 | (10 to 66) |
1 Persons testing negative for influenza and SARS-CoV-2 using molecular assays.
2 Multivariable logistic regression models adjusted for Census region, age, sex, race/ethnicity, and month.
3 Includes active solid-organ cancer, active hematologic cancer, solid-organ transplant, bone marrow/stem cell transplant, HIV infection, congenital immunodeficiency syndrome, use of an immunosuppressive medication within the last 30 days, splenectomy, graft-versus-host disease (currently or in the past), or any other condition that causes moderate or severe immunosuppression.
VISION Vaccine Effectiveness Network
Vaccine Effectiveness | ||||||
---|---|---|---|---|---|---|
Influenza positive | Influenza negative | Adjusted1 | ||||
N vaccinated /Total | (%) | N vaccinated /Total | (%) | VE % | 95% CI | |
All adults ≥ 18 years | 3278/14011 | (23) | 15752/43196 | (36) | 44 | (41 to 47) |
18-64 years | 1600/10590 | (15) | 6695/27545 | (24) | 46 | (42 to 49) |
≥ 65 years | 1678/3421 | (49) | 9057/15651 | (58) | 39 | (34 to 43) |
Immunicompromised2 | 64/179 | (36) | 553/1363 | (41) | 30 | (-2 to 52) |
1 Adjusted for patient age, study site, and calendar time.
2 Defined as at least one discharge diagnosis for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.
Vaccine Effectiveness | ||||||
---|---|---|---|---|---|---|
Influenza positive | Influenza negative | Adjusted1 | ||||
N vaccinated /Total | (%) | N vaccinated /Total | (%) | VE % | 95% CI | |
All adults ≥ 18 years | 671/1760 | (38) | 4561/9377 | (49) | 39 | (31 to 45) |
18-64 years | 146/623 | (23) | 802/2739 | (29) | 29 | (12 to 43) |
≥ 65 years | 525/1137 | (46) | 3759/6638 | (57) | 42 | (34 to 49) |
Immunicompromised2 | 130/297 | (44) | 1172/2316 | (51) | 31 | (10 to 48) |
1 Adjusted for patient age, study site, and calendar time.
2 Defined as at least one discharge diagnosis for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.
McLean HQ, Petrie JG, Hanson KE, et al. Interim Estimates of 2022–23 Seasonal Influenza Vaccine Effectiveness — Wisconsin, October 2022–February 2023. MMWR Morb Mortal Wkly Rep 2023;72:201–205. DOI: http://dx.doi.org/10.15585/mmwr.mm7208a1.